Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C23H27ClO7
CAS Number:
Molecular Weight:
450.91
MDL number:
NACRES:
NA.21
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
General description
Empagliflozin is a C-glucoside with a carbon-carbon bond between the glucose and aglycone, resisting the breakdown in the gastrointestinal tract.
Application
Empagliflozin may be used to study its effects on diabetes mellitus in animal models.
Biochem/physiol Actions
Empagliflozin (BI 10773) is an orally active, potent and highly selective sodium glucose co-transporter-2 inhibitor (hSGLT-2 IC50 = 3.1 nM; hSGLT-1/4/5/6 IC50 = 8.3/11/1.1/2.0 µM) that targets SGLT-2 with high affinity in a glucose-competitive manner (hSGLT-2 Kd = 57/194 nM in the absence/presence of 20 mM glucose). Empagliflozin improves glycaemic control in type 2 (1-3 mg/kg via daily p.o. to Zucker diabetic fatty (ZDF) rats) and type 1 (10 mg/kg b.i.d. p.o. to streptozotocin-induced diabetic (STD) rats) diabetes mellitus models.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
L Thomas et al.
Diabetes, obesity & metabolism, 14(1), 94-96 (2011-10-12)
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. This series of studies was conducted to assess the in vivo pharmacological effects of single or multiple doses of empagliflozin
G Luippold et al.
Diabetes, obesity & metabolism, 14(7), 601-607 (2012-01-25)
Sodium glucose cotransporter-2 (SGLT-2) is key to reabsorption of glucose in the kidney. SGLT-2 inhibitors are in clinical development for treatment of type 2 diabetes mellitus (T2DM). The mechanism may be of value also in the treatment of type 1
R Grempler et al.
Diabetes, obesity & metabolism, 14(1), 83-90 (2011-10-12)
Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This study assessed pharmacological properties of empagliflozin in vitro and pharmacokinetic properties in vivo and compared its potency and selectivity
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service